ArticleGynecologic oncology reports2026

Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report.

Alice P Barr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.